The Administrative Core (Core A) is directed by Roy Herbst, Principal Investigator of the Yale SPORE in Lung Cancer (YSILC), and co-directed by Ed Kaftan, with support from the program financial management team. Careful oversight by the Administrative Core will be critical to ensure the success of the Yale SPORE in Lung Cancer. Core A is an extension of existing infrastructure provided by YCC Research Administration to support and facilitate transdisciplinary research efforts. The Administrative Core serves as the central coordination point for all YSILC investigators, with responsibility for monitoring the progress of all projects and cores toward a translational/clinical endpoint. The Core Director and Co-Director along with the YISLC Co-PI (Dr. Chen) have responsibility for leading the YSILC program, setting translational research priorities, identifying new translational research opportunities from emerging data, monitoring the progress of all projects, cores and developmental projects and determining changes in direction of projects, cores and translational research as needed. Interactions among YSILC investigators is facilitated by Core A to accelerate the translation of laboratory findings into the proposed and future clinical studies. If required, the Core A Director will manage conflicts among YSILC investigators. As a team, the Core personnel monitors finances, maintains communications among project and core leaders and coordinates meetings, including the weekly lung cancer translational group seminar series, monthly meetings of the Executive Committee, annual meetings of the Internal/External Advisory boards and the annual YSILC SEP and DRP Symposium. In addition to these functions, the Core is the primary interface with the NCI, other lung cancer SPOREs, Yale Cancer Center and Yale University, and coordinates outreach efforts, including publications (internal and external), website development, seminars, patient/research advocacy activities, and fundraising programs. Through these administrative activities, Core A is essential to the organization of the YSILC program, to developing a widespread culture of lung cancer basic/clinical/translational research at Yale and to the efficient achievement of the stated program objectives, with the ultimate goal of a significant clinical impact for patients with lung cancer.

Public Health Relevance

The Administration Core (Core A) is essential for leading the Yale SPORE in Lung Cancer (YSILC). The Core provides scientific, financial and administrative oversight for all YSILC activities and make critical decisions regarding project oversight and management.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA196530-06
Application #
9854320
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Choe, Junho; Lin, Shuibin; Zhang, Wencai et al. (2018) mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature 561:556-560
Bade, Brett C; Hyer, J Madison; Bevill, Benjamin T et al. (2018) A Patient-Centered Activity Regimen Improves Participation in Physical Activity Interventions in Advanced-Stage Lung Cancer. Integr Cancer Ther 17:921-927
Fan, Pang-Dian; Narzisi, Giuseppe; Jayaprakash, Anitha D et al. (2018) YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proc Natl Acad Sci U S A 115:E6030-E6038
Tentori, Augusto M; Nagarajan, Maxwell B; Kim, Jae Jung et al. (2018) Quantitative and multiplex microRNA assays from unprocessed cells in isolated nanoliter well arrays. Lab Chip 18:2410-2424
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
O'Malley, Stephanie S; Zweben, Allen; Fucito, Lisa M et al. (2018) Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial. JAMA Psychiatry 75:129-138
Bondeson, Daniel P; Smith, Blake E; Burslem, George M et al. (2018) Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. Cell Chem Biol 25:78-87.e5
Wang, Jun; Sanmamed, Miguel F; Datar, Ila et al. (2018) Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. Cell :
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40

Showing the most recent 10 out of 74 publications